You are here » Home » Companies » Company Overview » Neuland Laboratories Ltd

Neuland Laboratories Ltd.

BSE: 524558 Sector: Health care
NSE: NEULANDLAB ISIN Code: INE794A01010
BSE LIVE 15:54 | 11 Dec 907.10 17.30
(1.94%)
OPEN

891.50

HIGH

932.20

LOW

891.50

NSE 15:51 | 11 Dec 902.95 13.50
(1.52%)
OPEN

900.00

HIGH

929.90

LOW

891.10

OPEN 891.50
PREVIOUS CLOSE 889.80
VOLUME 11061
52-Week high 1680.00
52-Week low 871.00
P/E 46.81
Mkt Cap.(Rs cr) 806
Buy Price 907.10
Buy Qty 146.00
Sell Price 0.00
Sell Qty 0.00
OPEN 891.50
CLOSE 889.80
VOLUME 11061
52-Week high 1680.00
52-Week low 871.00
P/E 46.81
Mkt Cap.(Rs cr) 806
Buy Price 907.10
Buy Qty 146.00
Sell Price 0.00
Sell Qty 0.00

Neuland Laboratories Ltd. (NEULANDLAB) - Company History

Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.'92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The company is closely working with several companies in Europe and North America for supply of active pharmaceutical ingredients and intermediates.